NeuroDerm Ltd. has announced that updated results from the Phase II Study assessing the safety, tolerability and pharmacokinetics (PK) of ND0612L will be presented at the American Academy of Neurology (AAN) 67th Annual Meeting taking place April 18 to 25, 2015 in Washington, DC.
ND0612L parkinson
ND0612L is the low-dose product candidate of NeuroDerm’s proprietary liquid Levodopa/Carbidopa (LD/CD) formulation that provides continuous, subcutaneously-delivered treatment for patients with moderate to severe Parkinson’s disease.
ND0612L has potential to reduce fluctuations of plasma levodopa concentrations in patients with Parkinson’s disease
The company previously announced positive topline results of the study at The Michael J. Fox Foundation’s 2014 Parkinson’s Disease Therapeutics Conference in October 2014. The data showed that patients with moderate to severe Parkinson’s disease who received continuous, subcutaneous doses of ND0612L exhibited clinically significant reduction in fluctuations of plasma levodopa concentrations compared to patients receiving placebo. Patients receiving ND0612L also experienced a corresponding in-clinic two-hour reduction over placebo in “off” time, improved sleep, better quality of life and global clinical improvement without an increase in troublesome dyskinesia.
The poster (P1.187), “Pharmacokinetics and Safety of ND0612L (LD/CD for Subcutaneous Infusion): Results from a Phase II Study in Moderate to Severe Parkinson’s Disease,” will be on display during Poster Session I – Movement Disorders: Parkinson’s Disease Pharmacotherapy from 2:00 to 6:30 PM EDT on Monday, April 20.
Lead investigator Nir Giladi, MD, Associate Professor in the Sackler Faculty of Medicine at Tel Aviv University and Chairman of the Department of Neurology at the Tel Aviv Sourasky Medical Center and Sheila Oren, MD, Vice President of NeuroDerm Clinical and Regulatory Affairs will be available to answer questions on the findings of the poster from 5:00 PM to 6:30 PM EDT.
